Press Releases

  • VolitionRx Demonstrates More Than 90% Accuracy for Colorectal Cancer NuQ(R) Blood Test in Completed Prospective Study

  • VolitionRx to Present at LD Micro Conference on December 3 in Los Angeles

  • VolitionRx Demonstrates NuQ® Blood Test Detects Lung Cancers with more than 90% Accuracy

  • VolitionRx Granted Its Second U.S. Patent

  • VolitionRx to Present at Two Conferences in November

  • VolitionRx Announces Third Quarter 2015 Financial Results and Business Update

  • VolitionRx Schedules Third Quarter 2015 Earnings Conference Call and Business Update for Wednesday, November 4, 2015 at 8:30am ET

  • VolitionRx Demonstrates NuQ® Blood Test Detects 95% of Pancreatic Cancers in Second Preliminary Study

  • VolitionRx Announces Publication of Results from Pancreatic Cancer Study with Lund University in Clinical Epigenetics

  • VolitionRx Announces First CE Mark for NuQ(R) Blood Assay for Detection of Colorectal Cancer